Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DNF8Z1
|
|||
| Drug Name |
ARO-APOC3
|
|||
| Drug Type |
RNA interference
|
|||
| Indication | Familial chylomicronemia syndrome [ICD-11: 5C80; ICD-10: J10, J11] | Phase 3 | [1] | |
| Hypertriglyceridemia [ICD-11: 5C80.1; ICD-10: E78.1, E78.3; ICD-9: 272.1, 427] | Phase 2 | [2] | ||
| Company |
Arrowhead Pharmaceuticals Pasadena, CA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | ApoC-III messenger RNA (APOC3 mRNA) | Target Info | Inhibitor | [3] |
| KEGG Pathway | PPAR signaling pathway | |||
| Reactome | Chylomicron-mediated lipid transport | |||
| HDL-mediated lipid transport | ||||
| Retinoid metabolism and transport | ||||
| WikiPathways | Statin Pathway | |||
| PPAR Alpha Pathway | ||||
| Visual phototransduction | ||||
| Lipid digestion, mobilization, and transport | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05089084) A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Familial Chylomicronemia Syndrome. U.S.National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT04720534) A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Severe Hypertriglyceridemia. U.S.National Institutes of Health. | |||
| REF 3 | ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets. Curr Atheroscler Rep. 2021 Mar 10;23(5):20. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.